Neurocrine Biosciences, Inc. (NBIX) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone, and welcome to Neurocrine Biosciences Report's first quarter 2025 results. At this time, all participants are in a listen-only mode. Later, you will have the opportunity to ask questions during the question and answer session. Please note, today's call will be recorded, and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Todd Tushla. Vice President of Investor Relations. Please go ahead. Thank you, and happy Cinco de Mayo to everyone. Welcome to Nurocrine Biosciences first quarter 2025 earnings call. With me today are Kyle Gaino, Chief Executive Officer, Matt Abernathy, Chief Financial Officer, Eric Benevich, Chief Commercial Officer, and for one last time as Chief Medical Officer, Ivory Roberts. During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings. Following prepared remarks, we will strive to get to everyone's questions. Now, I will turn the call over to Kyle. Thanks, Todd. Good afternoon, everyone. Nurocrin has never been in a stronger position as we maintain an enterprise-wide focus on execution and evolution. Even with external factors continuing to create market volatility, We remain focused on controlling what we can, executing with discipline to meaningfully deliver for both patients and shareholders. The first quarter reflected strong execution across both of our brands, with record new patient starts for Ingresa and encouraging early adoption of Chronicity. With reformed guidance for Ingresa and solid momentum heading into Q2, combined with an early but promising launch trajector...